The stock of Theravance Biopharma Inc (TBPH) has gone up by 3.91% for the week, with a 0.27% rise in the past month and a 23.75% rise in the past quarter. The volatility ratio for the week is 3.17%, and the volatility levels for the past 30 days are 2.87% for TBPH. The simple moving average for the last 20 days is 3.18% for TBPH’s stock, with a simple moving average of 19.54% for the last 200 days.
Is It Worth Investing in Theravance Biopharma Inc (NASDAQ: TBPH) Right Now?
TBPH has 36-month beta value of 0.01. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy”, 1 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for TBPH is 45.90M, and currently, short sellers hold a 8.66% ratio of that float. The average trading volume of TBPH on July 04, 2025 was 293.20K shares.
TBPH stock’s latest price update
The stock price of Theravance Biopharma Inc (NASDAQ: TBPH) has jumped by 0.90% compared to previous close of $11.05. Despite this, the company has seen a gain of 3.91% in its stock price over the last five trading days. prnewswire.com reported 2025-06-26 that YUPELRI approved by China’s NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Theravance Biopharma incurs no commercial costs in China; Viatris is responsible for the launch and commercialization DUBLIN, June 26, 2025 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced that Viatris Inc. (“Viatris”), has secured regulatory approval from China’s National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China. This approval triggers a one-time $7.5 million milestone from Viatris to Theravance Biopharma, which is expected to be received in Q3 2025.
Analysts’ Opinion of TBPH
Many brokerage firms have already submitted their reports for TBPH stocks, with Leerink Partners repeating the rating for TBPH by listing it as a “Market Perform”. The predicted price for TBPH in the upcoming period, according to Leerink Partners is $10 based on the research report published on August 06, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see TBPH reach a price target of $21. The rating they have provided for TBPH stocks is “Buy” according to the report published on April 12th, 2024.
SVB Leerink gave a rating of “Outperform” to TBPH, setting the target price at $12 in the report published on May 23rd of the previous year.
TBPH Trading at 10.27% from the 50-Day Moving Average
After a stumble in the market that brought TBPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.67% of loss for the given period.
Volatility was left at 2.87%, however, over the last 30 days, the volatility rate increased by 3.17%, as shares surge +1.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.76% upper at present.
During the last 5 trading sessions, TBPH rose by +3.91%, which changed the moving average for the period of 200-days by +36.98% in comparison to the 20-day moving average, which settled at $10.81. In addition, Theravance Biopharma Inc saw 30.87% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TBPH starting from Farnum Rhonda, who sold 24,000 shares at the price of $11.00 back on Jun 02 ’25. After this action, Farnum Rhonda now owns 336,918 shares of Theravance Biopharma Inc, valued at $264,000 using the latest closing price.
RHONDA FARNUM, the Officer of Theravance Biopharma Inc, proposed sale 24,000 shares at $11.00 during a trade that took place back on Jun 02 ’25, which means that RHONDA FARNUM is holding N/A shares at $264,000 based on the most recent closing price.
Stock Fundamentals for TBPH
Current profitability levels for the company are sitting at:
- -0.72% for the present operating margin
- 0.59% for the gross margin
The net margin for Theravance Biopharma Inc stands at -0.89%. The total capital return value is set at -0.15%. Equity return is now at value -31.46%, with -16.32% for asset returns.
Based on Theravance Biopharma Inc (TBPH), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.68. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -37.07.
Currently, EBITDA for the company is -38.45 million with net debt to EBITDA at 1.43. When we switch over and look at the enterprise to sales, we see a ratio of 7.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.77.
Conclusion
To put it simply, Theravance Biopharma Inc (TBPH) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
